Pachymic acid is a lanostrane-type triterpenoid fromP. cocos. Pachymic acid inhibitsAktandERKsignaling pathways.

Pachymic acid (PA) is able to inhibit gallbladder cancer tumorigenesis involving affection of Akt and ERK signaling pathways. Pachymic acid (PA) treatment significantly inhibits Rho A, Akt and ERK pathway in gallbladder carcinoma cells. Pachymic acid (PA) treatment can dose-dependently downregulate PCNA, ICAM-1, RhoA, p-Akt and pERK. Cell growth is inhibited by 10 μg/mL Pachymic acid (PA) 12 h after treatment, and a concentration of 30 μg/mL further reduced cell growth. The growth of cells is suppressed in a time- and dose-dependent manner. After 48 h treatment, about 25%, 40% and 70% of the cell growth are inhibited by Pachymic acid (PA) at concentration of 10 μg/mL, 20 μg/mL and 30 μg/mL, respectively. Pachymic acid (PA) also inhibits the growth of gallbladder carcinoma cells in a time-dependent and dose-dependent manner^[1].

To evaluate the anti-tumor activity of Pachymic acid (PA) in vivo, human lung cancer NCI-H23 tumor xenograft models are used. Pachymic acid (PA) significantly suppresses tumor growth at doses of 30 and 60 mg/kg for 21 days compared with the control group^[2].

528.76

Solid

C₃₃H₅₂O₅

29070-92-6

茯苓酸；茯灵酸

• Terpenoids
• Triterpenes

• Plants
• Polyporaceae
• Poria cocos

Room temperature in continental US; may vary elsewhere.

DMSO : 10 mg/mL(18.91 mM;ultrasonic and warming and heat to 60℃)

Ethanol : 4.17 mg/mL(7.89 mM;Need ultrasonic)

H₂O :< 0.1 mg/mL(insoluble)

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80℃, 6 months; -20℃, 1 month。-80℃ 储存时，请在 6 个月内使用，-20℃ 储存时，请在 1 个月内使用。

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照In Vitro方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用； 以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

• 1.

  请依序添加每种溶剂： 10% DMSO    40%PEG300   5%Tween-80   45% saline

  Solubility: 1 mg/mL (1.89 mM); Suspended solution; Need ultrasonic

  此方案可获得 1 mg/mL (1.89 mM) 的均匀悬浊液，悬浊液可用于口服和腹腔注射。

  以 1 mL 工作液为例，取 100 μL 10.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。

  将 0.9 g 氯化钠，完全溶解于 100 mL ddH2O 中，得到澄清透明的生理盐水溶液
• 2.

  请依序添加每种溶剂： 10% DMSO    90% (20%SBE-β-CDin saline)

  Solubility: 1 mg/mL (1.89 mM); Suspended solution; Need ultrasonic

  此方案可获得 1 mg/mL (1.89 mM) 的均匀悬浊液，悬浊液可用于口服和腹腔注射。

  以 1 mL 工作液为例，取 100 μL 10.0 mg/mL 的澄清 DMSO 储备液加到 900 μL20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。

  将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中，再用生理盐水定容至 10 mL，完全溶解，澄清透明
• 3.

  请依序添加每种溶剂： 10% DMSO    90%corn oil

  Solubility: ≥ 1 mg/mL (1.89 mM); Clear solution

  此方案可获得 ≥ 1 mg/mL (1.89 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。

  以 1 mL 工作液为例，取 100 μL 10.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。